Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Resmed Inc (RMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,417,669
  • Shares Outstanding, K 141,900
  • Annual Sales, $ 2,067 M
  • Annual Income, $ 342,280 K
  • 36-Month Beta 0.79
  • Price/Sales 6.09
  • Price/Cash Flow 24.50
  • Price/Book 6.14

Price Performance

See More
Period Period Low Period High Performance
1-Month
84.67 +18.52%
on 12/29/17
104.78 -4.23%
on 01/23/18
+15.24 (+17.91%)
since 12/22/17
3-Month
77.71 +29.13%
on 10/25/17
104.78 -4.23%
on 01/23/18
+20.53 (+25.72%)
since 10/23/17
52-Week
66.18 +51.63%
on 02/01/17
104.78 -4.23%
on 01/23/18
+36.75 (+57.78%)
since 01/23/17

Most Recent Stories

More News
Watch for Resmed Inc to Potentially Pullback After Gaining 17.99% Yesterday

Resmed Inc (NYSE:RMD) traded in a range yesterday that spanned from a low of $97.37 to a high of $104.78. Yesterday, the shares gained 18.0%, which took the trading range above the 3-day high of $89.72...

RMD : 100.35 (+14.67%)
ResMed (RMD) Beats Q2 Earnings & Sales on Growth in All Lines

ResMed (RMD) beats earnings and sales in Q2 on solid contributions from domestic and international businesses.

AMED : 55.83 (-1.31%)
RMD : 100.35 (+14.67%)
BIO : 254.83 (+0.07%)
ISRG : 439.55 (+1.29%)
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2018

ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2017. Revenue for the quarter was $601.3 million, a 13 percent increase compared to the same period of the prior...

RMD : 100.35 (+14.67%)
Why Earnings Season Could Be Great for ResMed (RMD)

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

RMD : 100.35 (+14.67%)
Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?

ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.

HSIC : 76.30 (-0.14%)
MYGN : 40.37 (+1.23%)
RMD : 100.35 (+14.67%)
BIO : 254.83 (+0.07%)
ResMed Announces Its Premier Portable Oxygen Concentrator, Mobi

ResMed (NYSE: RMD, ASX: RMD) today introduced Mobi, its first ResMed-branded portable oxygen concentrator (POC).

RMD : 100.35 (+14.67%)
SmarTrend Watching for Potential Pullback in Shares of Resmed Inc After 1.05% Gain

Resmed Inc (NYSE:RMD) traded in a range yesterday that spanned from a low of $86.12 to a high of $87.45. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $86.85...

RMD : 100.35 (+14.67%)
ResMed to Announce Second Quarter Fiscal Year 2018 Results

ResMed (NYSE: RMD) today announced it will report its second quarter of fiscal year 2018 results on Monday, January 22, 2018, after the New York Stock Exchange market closes. A press release with ResMed's...

RMD : 100.35 (+14.67%)
Diagnosing, Treating Sleep Apnea in Hospital Improves Survival, Says Study Published by American Journal of Medicine

Undiagnosed sleep apnea is highly prevalent among hospital patients, and treating it after they're discharged can improve their chances of long-term survival, according to a ResMed-funded (NYSE: RMD, ASX:...

RMD : 100.35 (+14.67%)
ResMed (RMD) Rides on Innovation Amid Reimbursement Woes

ResMed (RMD) achieves strong global revenue growth for the past few quarters on the back of sales of sleep devices, respiratory care devices, mask systems and software solutions.

PETS : 50.66 (+5.30%)
MYGN : 40.37 (+1.23%)
LMNX : 20.47 (-0.44%)
RMD : 100.35 (+14.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

See More

Business Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It...

See More

Key Turning Points

2nd Resistance Point 108.24
1st Resistance Point 104.30
Last Price 100.35
1st Support Level 96.89
2nd Support Level 93.42

See More

52-Week High 104.78
Last Price 100.35
Fibonacci 61.8% 90.03
Fibonacci 50% 85.48
Fibonacci 38.2% 80.93
52-Week Low 66.18

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.